jueves, 16 de marzo de 2017

Ahead of Print -Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies - Volume 23, Number 4—April 2017 - Emerging Infectious Disease journal - CDC

Ahead of Print -Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies - Volume 23, Number 4—April 2017 - Emerging Infectious Disease journal - CDC



Volume 23, Number 4—April 2017

Perspective

Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies

Scott B. HalsteadComments to Author 
Author affiliation: Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Abstract

The sudden appearance of overt human Zika virus infections that cross the placenta to damage fetal tissues, target sexual organs, and are followed in some instances by Guillain-Barré syndrome raises questions regarding whether these outcomes are caused by genetic mutations or if prior infection by other flaviviruses affects disease outcome. Because dengue and Zika viruses co-circulate in the urban Aedes aegypti mosquito–human cycle, a logical question, as suggested by in vitro data, is whether dengue virus infections result in antibody-dependent enhancement of Zika virus infections. This review emphasizes the critical role for epidemiologic studies (retrospective and prospective) in combination with the studies to identify specific sites of Zika virus infection in humans that are needed to establish antibody-dependent enhancement as a possibility or a reality.
Recently, polyclonal and monoclonal dengue virus (DENV)–elicited antibodies have been shown to neutralize or enhance Zika virus infection in vitro (1,2). Three studies have shown that monoclonal antibodies to the DENV fusion loop epitope reliably enhanced Zika virus infection (i.e., antibody-dependent enhancement [ADE]) in Fc receptor–bearing K-562 human myelogenous leukemia cells or the U-937 human monocytic cell line (13). By contrast, broadly neutralizing DENV monoclonal antibodies directed at a conformational quaternary epitope on the virion formed at the interface of 2 envelope dimer epitopes (EDE1 and EDE2) potently neutralized Zika virus in a picomolar range similar to the neutralization of DENV (2). X-ray crystallographic structures of antigen binding fragments of EDE1 and EDE2 in complex with the Zika virus envelope protein have been obtained (4). These observations raise important questions about the past and future of human infections with Zika virus.
Outside Africa, Zika virus occupies the same epidemiologic niche as do the DENVs. During the ongoing pandemic in the Western Hemisphere, infections in the sequence of DENV followed by Zika virus must have occurred often and will continue to occur. Might placental transfer of Zika virus or Guillain-Barré syndrome (GBS), fueled by the ADE phenomenon, occur specifically in DENV-immune persons? If Zika virus infections are enhanced by DENV antibodies, might ADE also occur after administering a dengue vaccine? Indeed, if Zika virus infections can be enhanced by DENV antibodies, might that also be an outcome following administration of a poorly protective Zika virus vaccine? Correspondingly, might Zika virus antibodies enhance DENV infections? These crucial questions require biologically valid answers. What information do we need to answer them, and where shall we start looking?
Zika virus, a member of the Flavivirus genus, is maintained in complex African zoonotic cycles, spilling from time to time into the Aedes aegypti mosquito urban transmission cycle (5). This spillover might be a very old phenomenon. Because many flaviviruses infect humans in Africa, it was logical to ask if antibodies to these viruses enhanced Zika virus infections. The answer obtained in vitro was affirmative (6). After having been first isolated in Africa in 1947, human Zika virus disease remained sparse and mild, with no reports of diverse clinical syndromes associated with infection (7). Nor was Zika disease reported from India or Southeast Asia, where Zika virus and DENV co-circulated, evidenced by detection of neutralizing antibodies in humans as early as 1954 (810). Zika virus was isolated from Ae. aegypti mosquitoes collected in rural Malaysia in 1966 (11). No alarms were raised in Asia until 2007, on the Yap Islands in the Western Pacific, when it was estimated that ≈900 cases of a mild febrile exanthema caused by Zika virus infections had occurred among a total population of ≈7,000 (12). Then, during 2013–2014, on Tahiti, a Zika virus epidemic was followed in 4 weeks by an outbreak of GBS (13). Of the 42 case-patients with Zika virus infection and subsequent GBS, 95% had evidence of prior DENV infection, although this percentage did not differ from that of controls (13). This illness phenomenon spread to South America, where remarkably, GBS often followed acute Zika virus infections by only a few days (1417). Then, abruptly, in Brazil, Zika virus was found to destroy fetal tissues (18). Next, it was learned that Zika virus infected the male reproductive tract and could be sexually transmitted (19).
Is the expanded pathogenicity of Zika virus the result of viral mutations, or might DENV ADE play a role, or are both true? An opinion has emerged that Zika virus genomes in Asia have acquired 1 or more mutations, contributing to its newly emerged pathogenicity (5,20). A recent analysis of full-length RNA sequences of 84 Zika virus genomes in Africa, Asia, the Pacific region, and the Americas has noted a stable amino acid change in the matrix protein of Asian viruses that accompanied placental invasiveness and GBS in Tahiti and the Americas (21). It is not clear what specific biologic properties might have been acquired by Zika virus that contributed to the observed new behaviors. The original strain of Zika virus recovered in Uganda in 1947 was neurotropic for 6-week-old mice (22). A strain genetically similar to the prototype in Africa productively infected human neural progenitor cells in vitro, dysregulating cell growth (23). In type 1 interferon receptor knockout mice or mice inoculated with type 1 interferon receptor–blocking antibodies, subcutaneous inoculation of a strain of Zika virus from French Polynesia infected maternal trophoblasts and resulted in apoptosis. In infected pregnant female mice, Zika virus crossed into the fetal circulation, where it infected endothelial cells, resulting in apoptosis and greatly impaired fetal circulation leading to ischemia and fetal loss (24).
Knowledge that a microbial disease is worsened by ADE derives from 2 evidentiary pillars: 1) epidemiologic evidence demonstrating that a unique syndrome or severe disease is significantly associated with persons who circulate antibodies (presumably “enhancing”) before infection, and 2) evidence of in situ replication by the causative organism in myeloid cells that serve as major targets of cellular infection. DENV disease enhancement was established by recording a strong association between severe disease in humans and a secondary-type DENV antibody response, by direct association of severe cases with sequential DENV infections in prospective cohort studies, and by the occurrence of severe disease during first DENV infections in infants born to dengue-immune mothers (2530). This latter observation provides population-level evidence that DENV antibodies are the critical risk factor for the occurrence of severe DENV disease. However, severe disease in infants occurs only when infants acquire antibodies acquired by 2 or more lifetime DENV infections in the mother (25,30). Importantly, the same IgG antibodies that enhance DENV infections in infants are protective for the first several months after birth (29). Evidence that myeloid cells support intracellular DENV infection in vivo in humans derives from studies on tissues from virologically documented patients obtained during surgery, at autopsy, or by venesection (3134). These studies, although few, are buttressed by the demonstration that DENV immune complex infection of Fc receptor–bearing cells leads directly to vascular permeability in mouse models (32,3540).
To establish whether ADE caused by DENV antibodies modifies the course of Zika virus infections, evidence will be required from the same 2 pillars. The outcomes of DENV–Zika virus sequential infections might be diverse and complicated. First, antibodies derived from monotypic infections with each of the 4 DENV serotypes, if they enhance at all, might affect Zika virus infections differently. As an example, infections in the sequence DENV-1 followed by DENV-2 or DENV-3 then DENV-2 result in more severe clinical outcome than infections in any of the other 10 secondary infection sequences (41). Second, the interval between DENV followed by Zika virus infection might regulate disease severity. In dengue, the interval between initial and a heterotypic DENV infection exerts a remarkable bidirectional effect. Sequential DENV infections at a short interval (<2 years) blunt the clinical severity of responses to a second infection, whereas as the interval widens (2–20 years), the outcome becomes increasingly severe (4244). Third, Zika virus infection enhancement could be critically dependent upon the parity of past DENV infections of the host. For example, as is true for dengue, a single prior DENV experience might enhance infection, whereas antibodies deriving from >2 past DENV infections might protect against further infection (45).
By using a simple protocol (Table), it should be possible to gather evidence using a case-control format comparing the frequency of a secondary flavivirus antibody response in convalescent-phase serum samples of persons experiencing any defined acute Zika virus disease syndromes, such as exanthematous fever, congenital Zika syndrome, or GBS (i.e., case-patients) with the prevalence of past DENV infection in Zika virus–infected age-, sex-, residence-, and ethnicity-matched persons from the same exposure group (i.e., controls). Such a comparison should be undertaken promptly in several different Zika virus–endemic locales. If these studies fail to provide evidence that prior flavivirus infection is a risk factor for any of the defined clinical outcomes of Zika virus infections, the search for Zika virus ADE can halt. However, if evidence compatible with ADE is obtained, it will be important to investigate the possibly complicated interactions between DENV and Zika virus infections alluded to here.
In the case of DENV, the ADE phenomenon requires infection of myeloid cells by infectious immune complexes; therefore, it will important to determine if myeloid cells are major targets of Zika virus syndromes in humans. DENV and Zika virus infections are each expressed clinically as febrile exanthema. In monkey and human DENV infections, infected peripheral blood leukocytes circulate transiently just before the appearance of virus in the skin (monkeys) or the appearance of a generalized body rash (humans) (33,46). In children in Nicaragua, DENV-infected peripheral blood leukocytes circulating late in the viremic period were definitively identified as monocytes (33). This finding might be a general phenomenon in viral exanthmata given that infected monocytes also circulate in blood during the rash stage in children with measles (47,48). A plausible hypothesis is that maculopapular rashes derive from DENV-infected monocytes originating in the bone marrow that are targeted to skin. By analogy, human Zika virus pathogenesis might involve myeloid cells and blood monocytes as infection targets. A search to prove or disprove this hypothesis should be undertaken promptly.
Should Zika virus infect circulating monocytes, this still leaves unanswered the question whether tissue macrophages are an important component of so-called “normal” Zika virus human infections. In A129 mice lacking type 1 interferon receptors, peripheral inoculation of Zika virus produced observable illness and high titers of virus in spleen, liver, and brain, but no attempt was made to identify target cells (49). As suggested by excretion of Zika virus in seminal fluid, urine, saliva, and tears, Zika virus might predominantly infect nonmyeloid tissues. As reviewed briefly here, there is ample evidence from studies on human uterine contents, plus validation in mouse models, that Zika virus infects neuronal tissues, a wide range of fetal organs, placental cells, endothelial cells, and reproductive organs. Clearly, we have much to learn about the pathogenesis and pathology of human Zika virus infections. The issue of ADE poses a unique challenge to researchers, the resolution of which rests in the first instance on epidemiologic evidence.
Dr. Halstead is an adjunct professor in the Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences. As a consultant to the Rockefeller Foundation, he founded the Pediatric Dengue Vaccine Initiative in 2003. His career interests have included arbovirology, epidemiology, vaccinology, and international health. He is a member of the Editorial Board of the Emerging Infectious Diseases Journal.

References

  1. Priyamvada LQuicke KMHudson WHOnlamoon NSewatanon JEdupuganti Set al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A2016;113:78527DOIPubMed
  2. Dejnirattisai WSupasa PWongwiwat WRouvinski ABarba-Spaeth GDuangchinda Tet al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol2016;17:11028DOIPubMed
  3. Paul LMCarlin ERJenkins MMTan ALBarcellona CMNicholson COet al. Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology2016;5:e117DOIPubMed
  4. Barba-Spaeth GDejnirattisai WRouvinski AVaney MCMedits ISharma Aet al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature2016;536:4853DOIPubMed
  5. Musso DGubler DJZika Virus. Clin Microbiol Rev2016;29:487524DOIPubMed
  6. Fagbami AHHalstead SBMarchette NJLarsen KCross-infection enhancement among African flaviviruses by immune mouse ascitic fluids.Cytobios1987;49:4955.PubMed
  7. Fagbami AHZika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. J Hyg (Lond)1979;83:2139DOIPubMed
  8. Smithburn KCKerr JAGatne PBNeutralizing antibodies against certain viruses in the sera of residents of India. J Immunol1954;72:24857.PubMed
  9. Smithburn KCNeutralizing antibodies against arthropod-borne viruses in the sera of long-time residents of Malaya and Borneo. Am J Hyg1954;59:15763.PubMed
  10. Hammon WMSchrack WD JrSather GESerological survey for a arthropod-borne virus infections in the Philippines. Am J Trop Med Hyg1958;7:3238.PubMed
  11. Marchette NJGarcia RRudnick AIsolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg1969;18:4115.PubMed
  12. Duffy MRChen THHancock WTPowers AMKool JLLanciotti RSet al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med2009;360:253643DOIPubMed
  13. Cao-Lormeau VMBlake AMons SLastère SRoche CVanhomwegen Jet al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet2016;387:15319DOIPubMed
  14. Brasil PSequeira PCFreitas ADZogbi HECalvet GAde Souza RVet al. Guillain-Barré syndrome associated with Zika virus infection. Lancet2016;387:1482DOIPubMed
  15. do Rosário MSde Jesus PAVasilakis NFarias DSNovaes MARodrigues SGet al. Guillain-Barré syndrome after Zika virus infection in Brazil. Am J Trop Med Hyg2016;95:115760DOIPubMed
  16. Parra BLizarazo JJiménez-Arango JAZea-Vera AFGonzález-Manrique GVargas Jet al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med2016;375:151323DOIPubMed
  17. Dos Santos TRodriguez AAlmiron MSanhueza ARamon Pde Oliveira WKet al. Zika Virus and the Guillain-Barré syndrome - case series from seven countries. N Engl J Med2016;375:1598601DOIPubMed
  18. Teixeira MGCosta MCde Oliveira WKNunes MLRodrigues LCThe epidemic of Zika virus–related microcephaly in Brazil: detection, control, etiology, and future scenarios. Am J Public Health2016;106:6015DOIPubMed
  19. Atkinson BHearn PAfrough BLumley SCarter DAarons EJet al. Detection of Zika virus in semen. Emerg Infect Dis2016;22:940DOIPubMed
  20. Russell PKThe Zika pandemic—a perfect storm? PLoS Negl Trop Dis2016;10:e0004589DOIPubMed
  21. Pettersson JHEldholm VSeligman SJLundkvist ÅFalconar AKGaunt MWet al. How Did Zika Virus Emerge in the Pacific Islands and Latin America? MBio2016;7:e0123916DOIPubMed
  22. Dick GWKitchen SFHaddow AJZika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg1952;46:50920DOIPubMed
  23. Tang HHammack COgden SCWen ZQian XLi Yet al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell2016;18:58790DOIPubMed
  24. Miner JJCao BGovero JSmith AMFernandez ECabrera OHet al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell2016;165:108191DOIPubMed
  25. Halstead SBNimmannitya SCohen SNObservations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med1970;42:31128.PubMed
  26. Halstead SBNeutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res2003;60:42167DOIPubMed
  27. Halstead SBCohen SNDengue hemorrhagic fever at 60 years: early evolution of concepts of causation and treatment. Microbiol Mol Biol Rev2015;79:28191DOIPubMed
  28. Kliks SCNimmanitya SNisalak ABurke DSEvidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg1988;38:4119.PubMed
  29. Halstead SBLan NTMyint TTShwe TNNisalak AKalyanarooj Set al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis2002;8:14749DOIPubMed
  30. Simmons CPChau TNThuy TTTuan NMHoang DMThien NTet al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis2007;196:41624DOIPubMed
  31. Jessie KFong MYDevi SLam SKWong KTLocalization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis2004;189:14118DOIPubMed
  32. Balsitis SJColoma JCastro GAlava AFlores DMcKerrow JHet al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg2009;80:41624.PubMed
  33. Durbin APVargas MJWanionek KHammond SNGordon ARocha Cet al. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology2008;376:42935DOIPubMed
  34. Aye KSCharngkaew KWin NWai KZMoe KPunyadee Net al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol2014;45:122133DOIPubMed
  35. Balsitis SJWilliams KLLachica RFlores DKyle JLMehlhop Eet al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog2010;6:e1000790DOIPubMed
  36. Kyle JLBeatty PRHarris EDengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis2007;195:180817DOIPubMed
  37. Orozco SSchmid MAParameswaran PLachica RHenn MRBeatty Ret al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol2012;93:21527DOIPubMed
  38. Shresta SSharar KLPrigozhin DMBeatty PRHarris EMurine model for dengue virus-induced lethal disease with increased vascular permeability.J Virol2006;80:1020817DOIPubMed
  39. Zellweger RMPrestwood TRShresta SEnhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe2010;7:12839DOIPubMed
  40. Martínez Gómez JMOng LCLam JHBinte Aman SALibau EALee PXet al. Maternal antibody-mediated disease enhancement in type I interferon-deficient mice leads to lethal disease associated with liver damage. PLoS Negl Trop Dis2016;10:e0004536DOIPubMed
  41. Guzman MGAlvarez MHalstead SBSecondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol2013;158:144559DOIPubMed
  42. Anderson KBGibbons RVCummings DANisalak AGreen SLibraty DHet al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis2014;209:3608DOIPubMed
  43. Grange LSimon-Loriere ESakuntabhai AGresh LPaul RHarris EEpidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol2014;5:280DOIPubMed
  44. Guzmán MGKourí GValdés LBravo JVázquez SHalstead SBEnhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica2002;11:2237 . DOIPubMed
  45. Gibbons RVKalanarooj SJarman RGNisalak AVaughn DWEndy TPet al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg2007;77:9103.PubMed
  46. Marchette NJHalstead SBFalkler WA JrStenhouse ANash DStudies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis1973;128:2330DOIPubMed
  47. Moench TRGriffin DEObriecht CRVaisberg AJJohnson RTAcute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA. J Infect Dis1988;158:43342DOIPubMed
  48. Esolen LMWard BJMoench TRGriffin DEInfection of monocytes during measles. J Infect Dis1993;168:4752DOIPubMed
  49. Dowall SDGraham VARayner EAtkinson BHall GWatson RJet al. A susceptible mouse model for Zika virus infection. PLoS Negl Trop Dis2016;10:e0004658DOIPubMed

Table

Suggested citation for this article: Halstead SB. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis. 2017 Apr [date cited]. http://dx.doi.org/10.3201/eid2304.161879
DOI: 10.3201/eid2304.161879


The table "Table. " is not cited in the text. Please add an in-text citation or delete the table.

No hay comentarios:

Publicar un comentario en la entrada